Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Johnson & Johnson's Stelara successful in mid-stage lupus study

Published 11/06/2017, 08:30 AM
© Reuters.  Johnson & Johnson's Stelara successful in mid-stage lupus study
  • Johnson & Johnson (NYSE:JNJ) unit Janssen Research & Development LLC announces positive results from a Phase 2 clinical trial assessing STELARA (ustekinumab) in patients with active systemic lupus erythematosus (SLE). The data are being presented at the 2017 ACR/ARHP Annual Meeting in San Diego, CA.
  • The study med the primary endpoint of demonstrating a statistically significantly higher proportion of patients in the treatment group experiencing improvements in lupus disease activity at week 24 compared to placebo (60% vs. 31%; p=0.0046).
  • The company plans to advance development into Phase 3.
  • Lupus is a chronic inflammatory autoimmune disorder that can affect a range of organs and body systems.
  • Ustekinumab, an IL-12 and IL-23 antagonist, is currently approved in the U.S. to treat plaque psoriasis, psoriatic arthritis and Crohn's disease.
  • Now read: What To Hold If You're Afraid Of An Upcoming Bear Market


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.